Celgene announces purchase of Juno Therapeutics for USD 9 billion
Date: 2018-01-23   Author: Saipriya Iyer  Category: #industry

Celgene announces purchase of Juno Therapeutics for USD 9 billion

In what may be regarded as a significant breakthrough being witnessed across healthcare industry, Celgene Corporation has reportedly decided to purchase Juno Therapeutics Incorporation, a biopharmaceutical firm headquartered in the U.S., for nearly USD 9 billion. Industry experts have stated that the former has entered a deal with the latter with an aim to gain a competitive edge in the cancer treatment sector. It has been anticipated that with the acquisition, the U.S. based biotechnology firm will gain a detailed insight into the cancer research therapies including CAR-T that utilizes the human’s own immune system to combat cancer tumors.

As per the terms & conditions of the pact, Celgene will have to pay USD 87 per share in cash to Juno, which is 91% more than the latter’s share price last displayed on the stock market January 16th, the day before Wall Street Journal stated the ongoing discussions between the firms related to the agreement. It has been known that the New Jersey based biotech company was increasing its research work on the creation of new drugs for treating cancer after its high revenue generating blood cancer medicine, Revlimid, failed the Phase II clinical trials conducted last month.

Reports have confirmed that both the firms have been associated with each other since 2015 for developing new therapies for treating cancer with Juno being the largest investor. Apparently, after the announcement of the deal Juno’s share price increased by 27% at USD 86.20, while the Celgene’s share price at USD 102.55 demonstrated a minimal change.

Industry professionals believe that the Celgene’s acquisition of Impact Biomedicines Inc.  followed by its purchase of Juno is a part of its business strategy to recover the revenue loss it had incurred due to the failed clinical tests for its best-selling blood cancer drug Revlimid. Furthermore, sources have stated that the acquisition agreement between both the firms is likely to be finalized in the first quarter of 2018. 



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Foam Tray Market Size Outlook 2025: Top Companies, Trends, Growth Factors Details by Regions, Types and Applications
Author: Partha Ray

This is a professional and in-depth study on the current state of the Foam Tray Market. Report initially provides a basic overview of the industry that covers definition, applications and manufacturing technology, post which the report explores in...


On-board Wireless Sensor Market Size, Growth, Analysis, Outlook by 2020 - Trends, Opportunities and Forecast to 2025
Author: Partha Ray

Global On-board Wireless Sensor Market 2019 Includes Market Size, Share, Trends, Growth, Demand, Supply, Application, Segmentation, Opportunity, Market Development, Production, Capacity Utilization, Supply, Analysis and Forecast by 2024

.


Waste Incinerators Market Size, Latest Trend, Growth by Size, Application and Forecast 2025
Author: Partha Ray

Market Study Report LLC adds a new report on Waste Incinerators Market Share for 2019-2024. This report provides a succinct analysis of the market size, revenue forecast, and the regional landscape of this industry. The report also highlights the ...